227 related articles for article (PubMed ID: 34228543)
1. Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.
Ganapathy US; Lan T; Krastel P; Lindman M; Zimmerman MD; Ho H; Sarathy JP; Evans JC; Dartois V; Aldrich CC; Dick T
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0097821. PubMed ID: 34228543
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.
Rominski A; Roditscheff A; Selchow P; Böttger EC; Sander P
J Antimicrob Chemother; 2017 Feb; 72(2):376-384. PubMed ID: 27999011
[TBL] [Abstract][Full Text] [Related]
3. ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant
Xie M; Ganapathy US; Lan T; Osiecki P; Sarathy JP; Dartois V; Aldrich CC; Dick T
Antimicrob Agents Chemother; 2023 Sep; 67(9):e0038123. PubMed ID: 37493373
[TBL] [Abstract][Full Text] [Related]
4. Repositioning rifamycins for Mycobacterium abscessus lung disease.
Ganapathy US; Dartois V; Dick T
Expert Opin Drug Discov; 2019 Sep; 14(9):867-878. PubMed ID: 31195849
[No Abstract] [Full Text] [Related]
5. C25-modified rifamycin derivatives with improved activity against
Paulowski L; Beckham KSH; Johansen MD; Berneking L; Van N; Degefu Y; Staack S; Sotomayor FV; Asar L; Rohde H; Aldridge BB; Aepfelbacher M; Parret A; Wilmanns M; Kremer L; Combrink K; Maurer FP
PNAS Nexus; 2022 Sep; 1(4):pgac130. PubMed ID: 36714853
[TBL] [Abstract][Full Text] [Related]
6. Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.
Ganapathy US; Lan T; Dartois V; Aldrich CC; Dick T
Microbiol Spectr; 2023 Sep; 11(5):e0190023. PubMed ID: 37681986
[TBL] [Abstract][Full Text] [Related]
7. Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.
Lan T; Ganapathy US; Sharma S; Ahn YM; Zimmerman M; Molodtsov V; Hegde P; Gengenbacher M; Ebright RH; Dartois V; Freundlich JS; Dick T; Aldrich CC
Angew Chem Int Ed Engl; 2022 Nov; 61(45):e202211498. PubMed ID: 36222275
[TBL] [Abstract][Full Text] [Related]
8. Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein.
Harbottle J; Mosaei H; Allenby N; Zenkin N
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0086421. PubMed ID: 34606341
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium abscessus HelR interacts with RNA polymerase to confer intrinsic rifamycin resistance.
Hurst-Hess KR; Saxena A; Rudra P; Yang Y; Ghosh P
Mol Cell; 2022 Sep; 82(17):3166-3177.e5. PubMed ID: 35905736
[TBL] [Abstract][Full Text] [Related]
10. Rifabutin Is Inactivated by Mycobacterium abscessus Arr.
Schäfle D; Selchow P; Borer B; Meuli M; Rominski A; Schulthess B; Sander P
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318008
[No Abstract] [Full Text] [Related]
11. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
[TBL] [Abstract][Full Text] [Related]
12. Rifamycin O, An Alternative Anti-
Hanh BTB; Park JW; Kim TH; Kim JS; Yang CS; Jang K; Cui J; Oh DC; Jang J
Molecules; 2020 Mar; 25(7):. PubMed ID: 32244387
[No Abstract] [Full Text] [Related]
13. In vitro activity of rifabutin against Mycobacterium abscessus, clinical isolates.
Chen J; Zhang H; Guo Q; He S; Xu L; Zhang Z; Ma J; Chu H
Clin Exp Pharmacol Physiol; 2022 Jul; 49(7):767-775. PubMed ID: 35531776
[TBL] [Abstract][Full Text] [Related]
14. Rifabutin Is Active against Mycobacterium abscessus in Mice.
Dick T; Shin SJ; Koh WJ; Dartois V; Gengenbacher M
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767722
[TBL] [Abstract][Full Text] [Related]
15. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
16. Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.
Johansen MD; Daher W; Roquet-Banères F; Raynaud C; Alcaraz M; Maurer FP; Kremer L
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816730
[No Abstract] [Full Text] [Related]
17. Modulation of a Mycobacterial ADP-Ribosyltransferase to Augment Rifamycin Antibiotic Resistance.
Zheng M; Lupoli TJ
ACS Infect Dis; 2021 Sep; 7(9):2604-2611. PubMed ID: 34355905
[TBL] [Abstract][Full Text] [Related]
18.
Cheng A; Tsai YT; Chang SY; Sun HY; Wu UI; Sheng WH; Chen YC; Chang SC
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670428
[TBL] [Abstract][Full Text] [Related]
19. Rifabutin Is Active against Mycobacterium abscessus Complex.
Aziz DB; Low JL; Wu ML; Gengenbacher M; Teo JWP; Dartois V; Dick T
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396540
[TBL] [Abstract][Full Text] [Related]
20. Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.
Pryjma M; Burian J; Thompson CJ
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
